Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria

LY191145 is the prototype of a series of compounds with activities against vancomycin-resistant enterococci derived by modification of the glycopeptide antibiotic LY264826. LY191145 had MICs for vancomycin- and teicoplanin-resistant enterococci of < or = 4 micrograms/ml for 50% of isolates and < or = 16 micrograms/ml for 90% of isolates. Its MICs for vancomycin-resistant, teicoplanin-susceptible enterococci were 1 to 8 micrograms/ml. LY191145 retains the potent activities of its parent compound against staphylococci and streptococci. In vivo studies in a mouse infection model confirmed these activities. This compound indicates the potential of semisynthetic glycopeptides as agents against antibiotic-resistant gram-positive bacteria.

[1]  R. Yao,et al.  Glycopeptides: Classification, Occurrence, and Discovery , 1994 .

[2]  N Woodford,et al.  Vancomycin-resistant enterococci , 1993, The Lancet.

[3]  R. Nagarajan.  Structure-activity relationships of vancomycin-type glycopeptide antibiotics. , 1993, The Journal of antibiotics.

[4]  K. Singh,et al.  Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Nosocomial enterococci resistant to vancomycin--United States, 1989-1993. , 1993, MMWR. Morbidity and mortality weekly report.

[6]  W. Noble,et al.  Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. , 1992, FEMS microbiology letters.

[7]  R. Wenzel,et al.  In-vitro activity of LY264826, an investigational glycopeptide antibiotic, against gram-positive bloodstream isolates and selected gram-negative bacilli. , 1992, The Journal of antimicrobial chemotherapy.

[8]  C. Watanakunakorn.  Comparison of LY264826-gentamicin with vancomycin-gentamicin against enterococci from blood cultures. , 1992, The Journal of antimicrobial chemotherapy.

[9]  H. Neu,et al.  In vitro activity of LY264826 compared to other glycopeptides and daptomycin. , 1991, Diagnostic microbiology and infectious disease.

[10]  P. Courvalin.  Resistance of enterococci to glycopeptides , 1990, Antimicrobial Agents and Chemotherapy.

[11]  K. Rolston,et al.  In vitro activity of LY264826, a new glycopeptide antibiotic, against gram-positive bacteria isolated from patients with cancer , 1990, Antimicrobial Agents and Chemotherapy.

[12]  N. Woodford,et al.  Resistance to vancomycin and teicoplanin: an emerging clinical problem , 1990, Clinical Microbiology Reviews.

[13]  D. M. Berry,et al.  The structural relationships of A82846B and its hydrolysis products with chloroorienticins A, B and C. , 1989, The Journal of antibiotics.

[14]  T. Nicas,et al.  Activity of glycopeptides against vancomycin-resistant gram-positive bacteria , 1989, Antimicrobial Agents and Chemotherapy.

[15]  D. Shlaes,et al.  Inducible resistance to vancomycin in Enterococcus faecium D366. , 1989, The Journal of infectious diseases.

[16]  D. M. Berry,et al.  Conversion of antibiotic A82846B to orienticin A and structural relationships of related antibiotics , 1989 .

[17]  J. Duval,et al.  Transferable vancomycin and teicoplanin resistance in Enterococcus faecium , 1989, Antimicrobial Agents and Chemotherapy.

[18]  J. Ott,et al.  Synthesis and antibacterial activity of N-acyl vancomycins. , 1988, The Journal of antibiotics.

[19]  A. Bernareggi,et al.  Pharmacokinetics of [14C]teicoplanin in male rats after single intravenous dose , 1986, Antimicrobial Agents and Chemotherapy.

[20]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .